New bank loans in China fell more than expected to the lowest in 22 months in October, but the drop was likely due to seasonal factors and policymakers are still expected to ramp up support for the cooling economy in coming months.
With stocks reaching all-time highs as we round out the calendar year, all eyes are on the market. But which names are worthy of all this investor attention? Wall Street analysts recommend focusing on the long-term outlook in order to zero in on high-growth tickers. We mean the stocks best positioned to dish out huge returns in the years to come. That being said, the economic uncertainty going into 2020 has made it increasingly difficult to pinpoint the names capable of leading the way. However, this is not to say that investment opportunities with stand-out growth prospects can’t be found.We …read more […]
AcelRx Pharmaceuticals, Inc.’s (NASDAQ:ACRX): AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses… …read more […]
Adidas plans to close high-tech “robot” factories in Germany and the United States it launched to bring production closer to customers, saying on Monday deploying some of the technology in Asia would be “more economic and flexible”.
Adidas plans to close high-tech “robot” factories in Germany and the United States it launched to bring production closer to customers, saying on Monday deploying some of the technology in Asia would be “more economic and flexible”. The Adidas factories were part of a drive to meet demand for faster delivery of new styles to its major markets and to counter rising wages in Asia and higher shipping costs. It originally planned a global network of similar factories. …read more […]
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) stock is about to trade ex-dividend in 3 days time. You will need to… …read more […]
Anyone interested in American Tower Corporation (REIT) (NYSE:AMT) should probably be aware that the Senior VP of… …read more […]
The big shareholder groups in NVIDIA Corporation (NASDAQ:NVDA) have power over the company. Generally speaking, as a… …read more […]
Shares across the globe fell on Monday, buffeted by escalating violence in Hong Kong that pushed Asian stocks to their worst day since August and stoked demand for the safe-haven yen and gold.
Nov.11 — Saudi Aramco released the prospectus for the state oil producer’s initial public offering, which is expected to kick off of Nov. 17. Bloomberg’s Annmarie Hordern has the details on “Bloomberg Markets: European Open.” …read more […]
Shares across the globe fell on Monday, buffeted by escalating violence in Hong Kong that pushed Asian stocks to their worst day since August and stoked demand for the safe-haven yen and gold. In the 24th straight week of pro-democracy unrest, Hong Kong police shot and wounded a protester as the Chinese-ruled territory saw rare working-hours violence. The MSCI world equity index, which tracks shares in 47 countries, slipped 0.2%, with Hong Kong’s Hang Seng index falling 2.7% and leading losses across Asia. …read more […]
International Exchange Inc said on Monday that oil majors including BP, Total and Shell would be partners in a new exchange it is launching in the United Arab Emirates next year to list Abu Dhabi National Oil Co’s (ADNOC) flagship Murban crude grade. The Murban futures contract, to be hosted on the new ICE Futures Abu Dhabi (IFAD), would replace retroactive pricing, allowing buyers to hedge risks and capture more value from ADNOC’s oil output, CEO Sultan al-Jaber told an energy forum in the United Arab Emirates capital Abu Dhabi. …read more […]
Prosus held firm on its $6.3 billion offer to buy Just Eat on Monday as it argued the merits of its bid versus one from Takeaway.com for the British online takeaway delivery firm.
Chinese retailer Alibaba Group Holding Ltd said on Monday that sales for its annual Singles’ Day shopping blitz crossed the $30 billion mark at 4:31 p.m. (0831 GMT), putting the event on track to set a record in its 11th year.
Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval for the investigational medicine this year, said its SUNFISH trial demonstrated statistically significant improvements in patients aged 2-25 years with Type 2 or 3 SMA, compared to a placebo. Biogen’s Spinraza, approved in 2016, lists at $750,000 in year one and $375,000 thereafter, while Novartis’s Zolgensma is the costliest one-time treatment at $2.1 million. …read more […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
